INTRODUCTION AND OBJECTIVES: Active surveillance (AS)
is becoming the de facto standard of care for men with low risk prostate cancer. Due to various risk factors, certain groups of men are deemed to be at higher risk for progression. These groups are considered by some to be poor candidates for active surveillance. We sought to determine predictors of subsequent upgrading in a multiracial group of men with low risk prostate cancer electing active surveillance protocol as treatment.
METHODS: A prospective database study was performed at the South Louisiana Veterans Administration Medical Center (SLVHCS), New Orleans, LA. Inclusion criteria for this study were at least two overall prostate biopsies, with a diagnostic biopsy demonstrating prostate cancer in any NCCN risk group. From the large multiracial database of 274 men on AS, 190 men were shown to have at least two overall biopsies and include into this study. Univariate and multivariate regressions were performed using R version 3.5.1 (Berkeley, CA). The specific tests were chosen to allow for detection of a significant risk factor for pathologic upgrade in both categorical and continuous variables.
RESULTS CONCLUSIONS: 19% of all patients treated by platinum-based chemotherapy due to testicular cancer suffered from a venous thromboembolic event, associated with reduced overall survival. As a result, monitoring of cancer patients at risk as well as the improvement of patients' awareness of a thromboembolic event should thus be the main goal of their treating physicians. Copyright © 2019 American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.
